WHO Issues First Child Obesity Guidelines: Lifestyle First, Drugs for Teens Only After Lifestyle Programs Fail

The World Health Organization has issued its first global guidelines on managing obesity in children and adolescents. The message is plain: the foundation of care is not a prescription or an operation.

"The foundation of obesity care for children and adolescents is not medicine or surgery, but access to comprehensive support that enables healthy eating, physical activity and sustainable behaviour change," said Dr. Luz María De Regil, director of WHO's Department of Nutrition and Food Safety.

What WHO recommends

For all children and adolescents with obesity, WHO strongly recommends structured dietary, physical activity and behavior-changing interventions, delivered individually or in a multimodal program. Digital health tools are conditionally recommended, with parent or caregiver supervision.

For children aged 0 to 9, WHO does not recommend drugs, bariatric surgery or weight-loss devices.

For adolescents aged 10 to 19, approved medicines may be considered only after a supervised lifestyle program has failed to deliver. Bariatric surgery may be considered under strict conditions for severe obesity.

De Regil told a press conference in Geneva that obesity drugs for teens should come into play only if the young person is mentally and physically prepared. WHO built the guidelines on an evaluation of 35 scholarly review articles. Health Policy Watch noted the research on drug treatment in children is still evolving.

The scale of the problem

WHO says 170 million children and adolescents aged 5 to 19 were living with obesity in 2024. That includes 70 million children aged 5 to 9 and 100 million adolescents aged 10 to 19. Prevalence in this age group has quadrupled since 1990, from 2% to 8%.

WHO calls obesity a "chronic, relapsing disease" that raises the risk of type 2 diabetes and cardiovascular disease. It also says affected children face stigma, discrimination and bullying, and that anxiety and depression can be both a cause and a consequence of the condition. Health workers, the guidelines say, should address obesity and mental health together, using family-engaged strategies.

Environment versus individual choices

WHO acknowledges that treating individual kids cannot reverse the trend. It calls for policies that make healthy diets and physical activity more accessible and affordable, including regulatory and fiscal measures and action across education, urban planning, transport and social protection. WHO has not said in the guidelines released so far which specific measures any country should adopt.

That framing is shared by at least one U.S. researcher. "It is important not to view adolescent obesity only as an individual lifestyle issue," said Ligang Liu of Western University of Health Sciences in California. "The environments in which young people eat, sleep, study, use technology, and spend time all influence risk."

The tradeoff is real. Fiscal and regulatory measures mean government taxing and mandating at scale, and the guidelines' own emphasis on family-engaged care points to the home as the front line.

U.S. teens: more of them showing organ damage

A JAMA Pediatrics research letter using National Health and Nutrition Examination Survey data tracked adolescents aged 12 to 19. Excess adiposity, defined as BMI-for-age at or above the 95th percentile plus a waist-to-height ratio of at least 0.50, rose from 14.2% in 1999-2000 to 18.2% in 2021-2023.

Clinical obesity, meaning excess fat accompanied by organ dysfunction, nearly doubled from 5.3% to 9.2%. Preclinical obesity, excess fat without organ dysfunction, held steady at about 9%.

The gap by income is stark. Among adolescents from low-income households, clinical obesity rose from 4.8% to 11.7%. Higher-income households saw no significant increase. Liu pointed to limited access to nutritious food, safe recreational spaces and specialty care as drivers.

BMI alone overcounts kids

A separate study in eClinicalMedicine, led by the Murdoch Children's Research Institute, applied the Lancet Commission's 2025 definition of clinical obesity to 786,557 participants. The data came from 11 cohorts in Australia, Canada, Estonia, Finland, the Netherlands, the UK and the US.

Clinical obesity affected 2.1% to 4.9% of children and adolescents, versus 7% to 10.8% classified obese by BMI. Among 4- and 5-year-olds, the figures were 3.7% versus 8.8%. The pattern flips with age. At 35 to 44, 26.3% met BMI criteria but 15.1% met the clinical definition. From age 55 on, clinical obesity is more common than BMI-defined obesity, reaching 52.0% among adults 65 to 74.

"BMI was useful for looking at obesity across entire countries, it failed to capture the full picture of a person's overall health," said Dr. Danielle Longmore of MCRI. She said the distinction could shape decisions on weight-loss medication and dietary advice.

The two studies use different datasets and criteria, and their adolescent numbers differ: 9.2% clinical obesity in the U.S. analysis versus 2.1% to 4.9% in the multinational range.

Prescriptions are moving faster than the evidence

WHO added GLP-1 drugs to its conditional recommendations for adults in 2025. For children, it had little research to judge safety or efficacy under age 10, Health Policy Watch reported. Novo Nordisk and Eli Lilly are both running trials in children as young as six.

Prescribing has not waited. A study in the journal Pediatrics found GLP-1 use among children aged 8 to 11 "increased sharply" between 2019 and 2026. Of a cohort of more than 3.5 million children with obesity and without diabetes, roughly 20,000 were prescribed the drugs.

That sets up the open question: WHO's guidance for under-10s is no drugs, yet thousands of 8- to 11-year-olds are already getting them, and the pediatric trials that would settle the safety question have not reported.